LEADER 03518nam  22004935  450 
001 9910337507003321
005 20200630065529.0
010   $a3-319-43896-4
024 7 $a10.1007/978-3-319-43896-2
035   $a(CKB)4100000007223495
035   $a(MiAaPQ)EBC5620170
035   $a(DE-He213)978-3-319-43896-2
035   $a(PPN)232964114
035   $a(EXLCZ)994100000007223495
100   $a20181214d2019      u|             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCancer Policy: Pharmaceutical Safety$b[electronic resource] /$fedited by June M. McKoy, Dennis P. West
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (129 pages)
225 1 $aCancer Treatment and Research,$x0927-3042 ;$v171
311   $a3-319-43894-8 
327   $aPharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe?  -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.
330   $aCancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
410  0$aCancer Treatment and Research,$x0927-3042 ;$v171
606   $aOncology  
606   $aPharmacy
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aDrug Safety and Pharmacovigilance$3https://scigraph.springernature.com/ontologies/product-market-codes/H69010
615  0$aOncology  .
615  0$aPharmacy.
615 14$aOncology.
615 24$aDrug Safety and Pharmacovigilance.
676   $a615.10289
702   $aMcKoy$b June M$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aWest$b Dennis P$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910337507003321
996   $aCancer Policy$91736112
997   $aUNINA